Vertex Pharmaceuticals Clocks 27% Growth In Product Revenues, Issues FY22 Guidance

Vertex Pharmaceuticals Incorporated VRTX posted Q4 FY21 product revenues increased 27% Y/Y to $2.07 billion, slightly better than the consensus of $2.00 billion.

  • The growth is primarily driven by the strong launches of Kaftrio in Europe and the performance of Trikafta in the U.S. 
  • Kaftrio/Trikafta sales jumped 55% to $1.69 billion. In contrast sales declined from Symdeko/Symkevi (-37% to $80 million), Orkambi (-32% to $147 million), and Kalydeco (-21% at $152 million).
  • The adjusted operating income increased 27% to $1.12 billion, while the margin remained almost stagnant at 54% in Q4.
  • Adjusted net income increased 31% to $866 million.
  • The Company held cash, cash equivalents, and marketable securities of $7.5 billion.
  • Combined non-GAAP R&D and SG&A expenses reached $703 million from $539 million reported a year ago.
  • Guidance: Vertex forecasts FY22 sales of $8.4 billion - $8.6 billion, with combined Non-GAAP R&D and SG&A expense of $2.70 to $2.75 billion.
  • The Company is advancing a broad clinical pipeline across six disease areas multiple programs in mid-and late-stage development, with clinical readouts expected in 2022.
  • Price Action: VRTX shares closed at $226.58 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!